AGL vs. TOI

Last updated Apr 2, 2026

Compare and contrast key facts about agilon health, inc. (AGL) and The Oncology Institute, Inc. (TOI).

Performance

AGL vs. TOI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in agilon health, inc. (AGL) and The Oncology Institute, Inc. (TOI). The values are adjusted to include any dividend payments, if applicable.

AGL vs. TOI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
AGL agilon health, inc.	-43.37%	-63.75%	-84.86%	-22.24%	-40.22%	6.55%
TOI The Oncology Institute, Inc.	-11.80%	1,052.10%	-84.85%	23.64%	-83.08%	-0.20%

Fundamentals

Market Cap AGL : $4.04B TOI : $3.19B
EPS AGL : -$0.94 TOI : -$0.06
PS Ratio AGL : 0.68 TOI : 6.08
Total Revenue (TTM) AGL : $5.93B TOI : $502.73M
Gross Profit (TTM) AGL : -$76.78M TOI : $53.67M
EBITDA (TTM) AGL : -$370.65M TOI : -$39.77M

Returns By Period

In the year-to-date period, AGL achieves a -43.37% return, which is significantly lower than TOI's -11.80% return.

AGL

• 1D: 23.26%
• 1M: -36.64%
• YTD: -43.37%
• 6M: -61.00%
• 1Y: -90.44%
• 3Y*: -74.58%
• 5Y*: —
• 10Y*: —

TOI

• 1D: 2.28%
• 1M: 6.44%
• YTD: -11.80%
• 6M: -9.77%
• 1Y: 149.21%
• 3Y*: 66.69%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AGL vs. TOI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AGL

AGL Risk / Return Rank: 8
AGL Sharpe Ratio Rank: 10
AGL Sortino Ratio Rank: 4
AGL Omega Ratio Rank: 4
AGL Calmar Ratio Rank: 4
AGL Martin Ratio Rank: 18

TOI

TOI Risk / Return Rank: 83
TOI Sharpe Ratio Rank: 84
TOI Sortino Ratio Rank: 85
TOI Omega Ratio Rank: 78
TOI Calmar Ratio Rank: 88
TOI Martin Ratio Rank: 82

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AGL vs. TOI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for agilon health, inc. (AGL) and The Oncology Institute, Inc. (TOI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AGL	TOI	Difference
Sharpe ratio Return per unit of total volatility	-0.74	1.54	-2.28
Sortino ratio Return per unit of downside risk	-1.63	2.45	-4.07
Omega ratio Gain probability vs. loss probability	0.78	1.28	-0.50
Calmar ratio Return relative to maximum drawdown	-0.96	3.52	-4.49
Martin ratio Return relative to average drawdown	-1.20	7.06	-8.26
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AGL vs. TOI - Sharpe Ratio Comparison

The current AGL Sharpe Ratio is -0.74, which is lower than the TOI Sharpe Ratio of 1.54. The chart below compares the historical Sharpe Ratios of AGL and TOI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AGL	TOI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.74	1.54	-2.28
Sharpe Ratio (All Time) Calculated using the full available price history	-0.70	-0.20	-0.50

Correlation

The correlation between AGL and TOI is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AGL vs. TOI - Dividend Comparison

Neither AGL nor TOI has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AGL vs. TOI - Drawdown Comparison

The maximum AGL drawdown since its inception was -99.27%, roughly equal to the maximum TOI drawdown of -98.79%. Use the drawdown chart below to compare losses from any high point for AGL and TOI.

Drawdown Indicators

	AGL	TOI	Difference
Max Drawdown Largest peak-to-trough decline	-99.27%	-98.79%	-0.48%
Max Drawdown (1Y) Largest decline over 1 year	-94.43%	-49.79%	-44.64%
Current Drawdown Current decline from peak	-99.10%	-71.22%	-27.88%
Average Drawdown Average peak-to-trough decline	-66.82%	-74.57%	+7.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	75.97%	24.84%	+51.13%

Volatility

AGL vs. TOI - Volatility Comparison

agilon health, inc. (AGL) has a higher volatility of 49.05% compared to The Oncology Institute, Inc. (TOI) at 27.26%. This indicates that AGL's price experiences larger fluctuations and is considered to be riskier than TOI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AGL	TOI	Difference
Volatility (1M) Calculated over the trailing 1-month period	49.05%	27.26%	+21.79%
Volatility (6M) Calculated over the trailing 6-month period	88.59%	60.60%	+27.99%
Volatility (1Y) Calculated over the trailing 1-year period	122.02%	97.86%	+24.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.06%	115.08%	-31.02%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.06%	115.08%	-31.02%

Financials

AGL vs. TOI - Profitability Comparison

The chart below illustrates the profitability comparison between agilon health, inc. and The Oncology Institute, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, agilon health, inc. reported a gross profit of 0.00 and revenue of 1.57B. Therefore, the gross margin over that period was 0.0%.

TOI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, The Oncology Institute, Inc. reported a gross profit of 0.00 and revenue of 141.96M. Therefore, the gross margin over that period was 0.0%.

AGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, agilon health, inc. reported an operating income of -197.92M and revenue of 1.57B, resulting in an operating margin of -12.6%.

TOI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, The Oncology Institute, Inc. reported an operating income of -6.91M and revenue of 141.96M, resulting in an operating margin of -4.9%.

AGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, agilon health, inc. reported a net income of -188.88M and revenue of 1.57B, resulting in a net margin of -12.0%.

TOI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, The Oncology Institute, Inc. reported a net income of -7.51M and revenue of 141.96M, resulting in a net margin of -5.3%.